Skip to main content

Advertisement

SpringerLink
Log in

Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aims of this study were to investigate the frequency and prognostic relevance of CD56 expression in patients with acute myeloid leukemia (AML) and to compare the importance of CD56 expression with standard prognostic factors, such as age, leukocytosis, cytogenetic abnormalities and performance status. We analyzed the data of 184 newly diagnosed patients with non-promyelocytic AML and a follow-up of 36 months. The median patient age was 58 years, with a range of 18–79. CD56+ antigen was recorded in 40 patients (21.7%). CD56 + was the most significant risk factor for OS: P = 0.05. The most significant factor for a poor rate of CR was age ≥ 55 years (P = 0.001). CD56 positivity had no significant influence on CR rate, but it was the most significant risk factor for disease-free survival (P = 0.005). The CD56 antigen is an independent prognostic risk factor, and its presence should be measured regularly for a better prognostic assessment of patients with AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Chang H, Salma F, Yi Q, Patterson B, Brien B, Minden MD. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res. 2004;28:43–8.

    Article  PubMed  CAS  Google Scholar 

  2. McCulloch EA, Kellecher CA, Miauchi J, Wang C, Cheng GYN, et al. Heterogeneity in acute myeloblastic leukemia. Leukemia. 1988;2(Suppl 12):36s–49s.

    Google Scholar 

  3. Raspadori D, Damiani D, Lenoci M, Rondeli D, Testoni N, et al. CD56 antigen expression in acute myeloid leukemia identifies patients with poor prognosis. Leukemia. 2001;15:1161–4.

    Article  PubMed  CAS  Google Scholar 

  4. Ciolli S, Leoni F, Nozzoli C, Longo G, Gianfaldoni G, et al. Prognostic impact of CD56 in 141 cases of acute myeloid leukemia. Haematologica. 2001;86(Suppl 10): a17 (abstract).

  5. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodighiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 2002;87:250–6.

    PubMed  CAS  Google Scholar 

  6. Reuss-Borst MA, Steinke B, Waller HD, Buhring HJ, Muller CA. Phenotypic and clinical heterogeneity of CD56-positive acute nonlymphoblastic leukemia. Ann Haematol. 1992;64:78–82.

    Article  CAS  Google Scholar 

  7. Dunphy CH, Gregowicz AJ, Rodriguez G. Natural killer cell acute leukemia with myeloid antigen expression. A previously undescribed form of acute leukemia. Hematopathology. 1995;104:212–5.

    CAS  Google Scholar 

  8. Cheson BD, Bennet JM, Kopecky KJ, Buchner T, Willman CL, et al. International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcome, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–9.

    Article  PubMed  Google Scholar 

  9. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. Proposals for the classification of the acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol. 1976;33:219–28.

    Article  Google Scholar 

  10. Donner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:454–74.

    Google Scholar 

  11. Jiang A, Jiang H, Branddwein J, Kamel-Reid S, Chang H. Prognostic factors in normal karyotype acute myeloid leukemia in absence of the FLT3-ITD mutation. Leuk Res. 2010. doi:10.1016/j.leukres.2010.07.021.

  12. Raspadori D, Damiani D, Micheli M, Stocchi R, Gentili S, et al. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica. 2002;87:1135–40.

    PubMed  CAS  Google Scholar 

  13. Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukemia patients. Haem Oncol. 2009;27:148–53.

    Article  Google Scholar 

  14. Klepin HD, Baldalucci L. Acute myelogenous leukemia in older adults. Oncologist. 2009;14:222–32.

    Article  PubMed  CAS  Google Scholar 

  15. Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. ASH Education Book. 2010;2010:56–61.

    Google Scholar 

  16. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. ASH Education Book. 2008;2008(1):1–11.

    Google Scholar 

  17. Bear MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, et al. Expression of the neural cell adhesion molecule 56 is associated with short remission duration and survival in acute myeloid leukemia with t(8:21) (q22:q22. Blood. 1997;90:1643–8.

    Google Scholar 

  18. Erba HP. Prognostic factors in elderly patients with AML and the implications for treatment. ASH Education Book. 2007;2007(1):420–8.

    Google Scholar 

  19. Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–8.

    Article  PubMed  Google Scholar 

  20. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, et al. The haematopoietic cell transplantation comorbidity index score predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukemia. Br J Haematol. 2007;136:624–7.

    Article  PubMed  Google Scholar 

  21. Etienne A, Esterni B, Charbonnier A, Mozziconacci MJ, Arnoulet C, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007;109:1376–83.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Ministry of Science and Technological Development of Republic of Serbia, N0 41004.

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Author information

Authors and Affiliations

  1. Clinic for Hematology, Clinical Center of Serbia, Koste Todorovica 2, 11000, Belgrade, Serbia

    Irena Djunic, Marijana Virijevic, Vladislava Djurasinovic, Natasa Colovic, Nada Kraguljac-Kurtovic, Ana Vidovic, Nada Suvajdzic-Vukovic & Dragica Tomin

  2. Faculty of Medicine, University of Belgrade, Belgrade, Serbia

    Natasa Colovic, Ana Vidovic, Nada Suvajdzic-Vukovic & Dragica Tomin

  3. Clinical Hospital Center “Zemun”, Belgrade, Serbia

    Aleksandra Novkovic

Authors
  1. Irena Djunic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marijana Virijevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vladislava Djurasinovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aleksandra Novkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Natasa Colovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nada Kraguljac-Kurtovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ana Vidovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nada Suvajdzic-Vukovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dragica Tomin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irena Djunic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Djunic, I., Virijevic, M., Djurasinovic, V. et al. Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia. Med Oncol 29, 2077–2082 (2012). https://doi.org/10.1007/s12032-011-0104-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0104-9

Keywords

Search

Navigation